Hydrocortisone supresses inflammatory activity of metalloproteinase - 8 in carotid plaque;Hidrocortisona suprime a atividade inflamatória da metaloproteinase - 8 presente na placa carotídea

Brazilian Journal of Cardiovascular Surgery

Volumn 30, Issue 3, 2015, Pages 295-303

  Gabriel, Sthefano Atique ^a   Antonangelo, Leila ^b   Capelozzi, Vera Luiza ^b   Beteli, Camila Baumann ^c   de Camargo Júnior, Otacílio ^a   de Aquino, José Luis Braga ^a   Caffaro, Roberto Augusto ^d  

^a PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d Instituto Dante Pazzanese de Cardiologia ^*  (Brazil)

Author keywords

Carotid; Carotid stenosis; Endarterectomy; Hydrocortisone; Inflammation; Matrix metalloproteinases

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GELATINASE B; HYDROCORTISONE; NEUTROPHIL COLLAGENASE;

AGED; CAROTID ENDARTERECTOMY; CAROTID STENOSIS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; INTERNAL CAROTID ARTERY; MALE; MIDDLE AGED; NONPARAMETRIC TEST; POSTOPERATIVE PERIOD; REFERENCE VALUE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; HYDROCORTISONE; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POSTOPERATIVE PERIOD; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940392424     PISSN: 01027638     EISSN: 16789741     Source Type: Journal    
DOI: 10.5935/1678-9741.20150034     Document Type: Article

References (22)

1. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18(28):4266-88.
2. Balanescu S, Calmac L, Constantinescu D, Marinescu M, Onut R, Dorobantu M. Systemic inflammation and early atheroma formation: are they related? Maedica (Buchar). 2010;5(4):292-301.
3. Hermus L, Lefrandt JD, Tio RA, Breek JC, Zeebregts CJ. Carotid plaque formation and serum biomarkers. Atherosclerosis. 2010;213(1):21-9.
4. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169(2):203-14.
5. Loftus IM, Naylor R, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31(1):40-7.
6. Chase AJ, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res. 2003;40(4):329-43.
7. Profumo E, Esposito C, Buttari B, Tosti ME, Ortona E, Margutti P, et al. Intracellular expression of cytokines in peripheral blood from patients with atherosclerosis before and after carotid endarterectomy. Atherosclerosis. 2007;191(2):340-7.
8. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008; 4(10):525-33.
9. Imamura K, Hayashi E, Suzumura A. Cytokine production by peripheral blood monocytes/macrophages in the patients with multiple sclerosis and its suppression by methylprednisolone. Jpn Clin Neurol. 1992;32(3):276-80.
10. Elenkov IJ. Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int. 2008;52(1-2):40-51.
11. Clinical alert: benefit of carotid endarterectomy for patients with high-grade stenosis of the internal carotid artery. National Institute of Neurological Disorders and Stroke, Stroke and Trauma Division. North American Symptomatic Carotid Endarterectomy Trial (NASCET) investigators. Stroke. 1991;22(6):816-7.
12. Kawamura T, Inada K, Okada H, Okada K, Wakusawa R. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth. 1995;42(5 Pt 1):399-403.
13. Komori K, Ishida M, Matsumoto T, Kume M, Ohta S, Takeuchi K, et al. Cytokine patterns and the effects of a preoperative steroid treatment in the patients with abdominal aortic aneurysms. Int Angiol. 1999;18(3):193-7.
14. Raja SG, Dreyfus GD. Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann. 2005;13(4):382-95.
15. Rubens FD, Mesana T. The inflammatory response to cardiopulmonary bypass: a therapeutic overview. Perfusion. 2004;19 Suppl 1:S5-12.
16. Liguori GR, Kanas AF, Moreira LF. Managing the inflammatory response after cardiopulmonary bypass: review of the studies in animal models. Rev Bras Cir Cardiovasc. 2014;29(1):93-102.
17. Heider P, Pelisek J, Poppert H, Eckstein HH. Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease. Vasc Endovascular Surg. 2009;43(6):551-60.
18. Taurino M, Raffa S, Mastroddi M, Visco V, Rizzo L, Torrisi MR, et al. Metalloproteinase expression in carotid plaque and its correlation with plasma levels before and after carotid endarterectomy. Vasc Endovascular Surg. 2008;41(6):516-21.
19. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37(1):235-9.
20. Jiang XB, Wang JS, Liu DH, Yuan WS, Shi ZS. Overexpression of matrix metalloproteinase-9 is correlated with carotid intraplaque hemorrhage in a swine model. J Neurointerv Surg. 2013;5(5):473-7.
21. Peeters W, Moll FL, Vink A, van der Spek PJ, de Kleijn DP, de Vries JP, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J. 2011;32(18):2314-25.
22. Alvarez B, Ruiz C, Chacón P, Alvarez-Sabin J, Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg. 2004;40(3):469-75.